BLUE - bluebird bio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
168.90
-18.45 (-9.85%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close187.35
Open186.90
Bid169.25 x 1200
Ask170.00 x 3000
Day's Range166.43 - 187.95
52 Week Range85.65 - 236.17
Volume2,655,784
Avg. Volume818,569
Market Cap8.465B
Beta2.83
PE Ratio (TTM)N/A
EPS (TTM)-8.34
Earnings DateJul 31, 2018 - Aug 6, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est219.72
Trade prices are not sourced from all markets
  • Benzingayesterday

    Evercore ISI Says Bluebird Bio Has Path To Commercialization, Madrigal Pharma Outpaced By Mid-Cap Alternatives

    Evercore ISI's Josh Schimmer on June 19 upgraded bluebird from In-line to Outperform with a price target lifted from $175 to $230. Bluebird's recent updates related to its LentiGlobin investigational gene therapy in patients with sickle cell disease and the separate myeloma CAR-T therapy bb2121 with its partner Celgene Corporation (NASDAQ: CELG) represent an "important positive inflection" for the company, Schimmer said in the upgrade note.

  • ACCESSWIRE4 days ago

    Today's Research Reports on Trending Tickers: bluebird bio and Exelixis

    NEW YORK, NY / ACCESSWIRE / June 21, 2018 / U.S. markets were mixed Wednesday as global trade concerns continue to be a focus. The Nasdaq and S&P 500 Index posted gains driven by deal making activities ...

  • ACCESSWIRE6 days ago

    Blog Exposure - bluebird bio Announces Encouraging New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin(TM) Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia

    LONDON, UK / ACCESSWIRE / June 19, 2018 / If you want access to our free research report on bluebird bio, Inc. (NASDAQ: BLUE), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BLUE as the Company's latest news hit the wire. On June 15, 2018, the Company announced that it will present new data from the completed Phase-1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase-3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, at the 23rd Annual Congress of the European Hematology Association in Stockholm on June 16, 2018. Active-Investors.com is currently working on the research report for BioPharmX Corporation (NYSE: BPMX), which also belongs to the Healthcare sector as the Company bluebird bio.

  • ACCESSWIRE6 days ago

    Free Technical Research on BioPharmX and Three More Biotech Equities bio

    LONDON, UK / ACCESSWIRE / June 19, 2018/ If you want a free Stock Review on BPMX sign up now at www.wallstequities.com/registration. On Monday, June 18, 2018, the Dow Jones Industrial Average and the S&P 500 edged 0.41% and 0.21% lower, respectively at the closing bell, while the NASDAQ Composite stayed bullish, finishing marginally lower by 0.01%. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), BioPharmX Corp. (NYSE AMER: BPMX), BioTime Inc. (NYSE AMER: BTX), and bluebird bio Inc. (NASDAQ: BLUE).

  • ACCESSWIRE10 days ago

    Today's Research Reports on Trending Tickers: Puma Biotechnology and bluebird bio

    NEW YORK, NY / ACCESSWIRE / June 15, 2018 / U.S. market ended mostly higher on Thursday, as rallies from tech sector drove the Nasdaq to new intraday and closing records. The Dow Jones Industrial Average ...

  • Business Wire10 days ago

    bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin™ Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia at Annual Congress of the European Hematology Association

    bluebird bio, Inc. (BLUE) announced that new data from the completed Phase 1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase 3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, will be presented in an oral session on June 16 at the 23rd Annual Congress of the European Hematology Association by Franco Locatelli, M.D., Ph.D., of the IRCCS Ospedale Pediatrico Bambino Gesù of Rome, Italy. “The maturing data from HGB-204 and HGB-207 suggest that one-time treatment with LentiGlobin may address the underlying genetic cause of TDT.

  • Business Wire10 days ago

    bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association

    bluebird bio, Inc. today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease will be presented in an oral presentation on Saturday, June 16 at the 23rd Congress of the European Hematology Association by Julie Kanter, M.D., Medical University of South Carolina, Charleston, South ...

  • Bloomberg11 days ago

    Hematology Conference Could Spur Some of Biotech's Outperformers

    Bluebird Bio Inc. and Global Blood Therapeutics Inc. will be among biotechnology companies in the spotlight this week as doctors and investors flock to Stockholm for presentations at the Congress of European Hematology Association. Bluebird is expected to release data from its pivotal trial of LentiGlobin in patients with beta-thalassemia and updates on an earlier study of the therapy in patients with severe sickle cell disease. Competitor Global Blood will report updated data on its sickle cell treatment in patients ages 12 to 17, which analysts expect to have read-through to highly anticipated late-stage data in adults that are expected later this month.

  • ACCESSWIRE20 days ago

    Today's Research Reports on Trending Tickers: Gilead Sciences and bluebird bio

    NEW YORK, NY / ACCESSWIRE / June 5, 2018 / Wall Street closed up Monday on the back of strong performances by the consumer discretionary and technology sectors. Investors appear to be focusing on positive ...

  • Business Wire20 days ago

    bluebird bio Announces Investor Events in June

    Investors may listen to the call by dialing (844) 825-4408 from locations in the United States or +1 (315) 625-3227 from outside the United States. To access the live webcasts of bluebird bio’s presentations and conference calls, please visit the “Events & Presentations” page within the Investors and Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcasts will be available on the bluebird bio website for 90 days following the events.

  • Benzinga20 days ago

    Bluebird Bio's Multiple Myeloma Data Reinforces Canaccord Genuity's Bullish Thesis

    Canaccord Genuity is maintaining its bullish stance on  bluebird bio Inc (NASDAQ: BLUE ) and projects upside for the biotech following a positive patient response to bb2121, the company’s multiple myeloma ...

  • Could Celgene Shake Up the CAR-T Market?
    Motley Fool20 days ago

    Could Celgene Shake Up the CAR-T Market?

    Two key updates at ASCO point to good prospects for Celgene's oncology pipeline.

  • MarketWatch20 days ago

    Bluebird Bio shares lift 9% on CAR-T cancer therapy results

    Bluebird Bio Inc. shares lifted 9% in Monday morning trade after the company and its partner, Celgene Corp. , released phase 1 clinical trial results for the CAR-T cell therapy bb2121 showing that median patients survived for 11.8 months without their cancer progressing. Celgene shares declined 0.7%. The trial focused on patients with late-stage relapsed/refractory multiple myeloma, and patients had tried several other treatments before bb2121, with a median of seven prior myeloma treatment regimens.

  • #ASCO18: A Weekend of Surprises
    Motley Fool21 days ago

    #ASCO18: A Weekend of Surprises

    Those watching this year's ASCO conference for market-moving news aren't going to be disappointed.

  • Is bluebird bio Inc (NASDAQ:BLUE) Worth $182.8 Based On Intrinsic Value?
    Simply Wall St.23 days ago

    Is bluebird bio Inc (NASDAQ:BLUE) Worth $182.8 Based On Intrinsic Value?

    In this article I am going to calculate the intrinsic value of bluebird bio Inc (NASDAQ:BLUE) using the discounted cash flows (DCF) model. If you want to learn more aboutRead More...

  • Business Wire23 days ago

    Updated Results of Ongoing Multicenter Phase I Study of bb2121 anti-BCMA CAR T Cell Therapy Continue to Demonstrate Deep and Durable Responses in Patients with Late-Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting

    Celgene Corporation and bluebird bio, Inc. today announced updated results from the ongoing CRB-401 phase I clinical study of bb2121, an investigational anti-B-cell maturation antigen CAR T cell therapy, in 43 patients with late-stage relapsed/refractory multiple myeloma.

  • Analysts’ Recommendations for Incyte in May
    Market Realist25 days ago

    Analysts’ Recommendations for Incyte in May

    Wall Street analysts expect the company to see a 40.9% rise in revenue to $459.8 million in Q2 2018. Incyte’s stock price has fallen nearly 51.7% over the last 12 months and nearly 29.6% in 2018 year-to-date. Wall Street analysts’ recommendations show a 12-month target price of $81.0 per share compared to its price of $66.67 per share on May 24.

  • Motley Fool26 days ago

    Something Borrowed, Something Blue, Volume 2: It's Been a Roller-Coaster Ride for BLUE Shareholders

    David reviews why the Fool continues to recommend the volatile bluebird bio and why he invests in companies like it.

  • Motley Fool26 days ago

    Something Old, Something New, Something Borrowed, Volume 2: A Particularly Motley Podcast

    It's an especially motley show today: a little of this, a little of that, thoughts from an old show, a new essay, some borrowed wisdom, and a BLUE stock pick. And, hey, what's that in your shoe?

  • What Analysts Think about Ionis
    Market Realistlast month

    What Analysts Think about Ionis

    In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million. Analysts expect Ionis’s top line to rise ~30.2% to ~$135.7 million in the second quarter. The chart below shows analysts’ recommendations for Ionis stock over the last year.

  • Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bio
    Motley Foollast month

    Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bio

    Which stock wins in a head-to-head match-up between these two clinical-stage biotechs?

  • Business Wirelast month

    FDA Grants Breakthrough Therapy Designation to Lenti-D™ for the Treatment of Cerebral Adrenoleukodystrophy

    bluebird bio, Inc. (BLUE) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Lenti-D™ for the treatment of patients with cerebral adrenoleukodystrophy (CALD), a rare, serious and life-threatening hereditary neurological disorder. Breakthrough Therapy designation is designed to expedite the development and review of a drug intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. “The founding of bluebird was inspired by the potential to develop a one-time gene therapy for boys suffering from this potentially fatal form of adrenoleukodystrophy,” said David Davidson, M.D., chief medical officer, bluebird bio.

  • BlueBird Bio Stock Jumps over 6% on May 17
    Market Realistlast month

    BlueBird Bio Stock Jumps over 6% on May 17

    BlueBird Bio (BLUE) is a biotechnology company focused on developing gene therapy, cancer immunotherapy, and gene editing for the treatment of serious diseases. On May 17, Bluebird Bio (BLUE) stock jumped over 6.1% to the closing price of $189.30 per share, following positive news.